Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14588427 | 0.88 | ESR2 (0.50) | THRBESR2MAPTALDH1A1KMT2A | |
| SCHEMBL14538449 | 0.86 | NPC1 (0.45) | THRBLMNAALDH1A1KDM4ESLC18A3 | |
| SCHEMBL39792 | 0.85 | THRB (0.59) | THRBLMNAALDH1A1KMT2ACYP1A2 | |
| SCHEMBL18511951 | 0.84 | THRB (0.43) | THRBESR2KMT2ATDP1CYP2C9 | |
| SCHEMBL2582818 | 0.84 | THRB (0.45) | THRBMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL12386504 | 0.84 | ESR2 (0.46) | THRBESR2ALDH1A1MEN1KMT2A | |
| SCHEMBL15397337 | 0.84 | THRB (0.50) | THRBLMNAESR2MAPTALDH1A1 | |
| SCHEMBL10000354 | 0.84 | ESR2 (0.46) | THRBESR2MAPTALDH1A1KMT2A | |
| SCHEMBL19621913 | 0.83 | THRB (0.42) | THRBESR2MAPTKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL19749007 | 0.83 | THRB (0.58) | THRBLMNAALDH1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | CCNE2, CCNE1, CCNL2 | THRB 1589/4885LMNA 828/4885CHRNA7 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.